As the world races to develop an antidote for the coronavirus, two potential COVID-19 vaccines have passed early-stage clinical trials and are on schedule to be made available in early 2021.
The vaccine, called ChAdOx1 nCoV-19, was conceived at Oxford University in the United Kingdom and will be manufactured by AstraZeneca.
In Phase I/II COV001 trial, the compound drug stimulated both neutralizing antibodies and active immune cells, or T-cells. Generating a robust immune response against the SARS-CoV-2 virus in all evaluated participants, while showing no significant side effects.
Late-stage Phase II/III trials are currently underway in the UK, Brazil and South Africa and are due to start in the US. Trials will define how well the vaccine will protect from the COVID-19 disease and measure safety and immune responses in different age ranges and at various doses.
If successful, the coronavirus vaccine will be made available early next year. More Info: AstraZeneca
The other vaccine that past pass early-stage clinical trials is being developed by Moderna. Identified as mRNA-1273, the medication induced anti–SARS-CoV-2 immune responses in all participants with no serious safety concerns identified.
The vaccine is designed to induce neutralizing antibodies to part of the protein the virus binds to enter human cells.
Moderna has completed the manufacture of the vaccine required to start the Phase 3 study, that it hopes to start this month. According to the Company’s press release, development for a COVID-19 vaccine remains on track to deliver doses, beginning in 2021. More Info: Moderna
Knowing what to look for is important, so people can get support to help them…
Image: Laura James With 10,000 healthcare workers already off the job amid the sixth wave of pandemic…
Photo: Anete Lusina If your employer invites you to attend a meeting, you MUST ask…
The C.D.C. also affirmed there is no need to quarantine at home following high-risk exposures…
Hospital executives who have hired Litvak describe him as a genius and a pioneer in…
Photo cottonbro / Pexels Many people focus on worst-case scenarios in the days following the…
This website uses cookies.